FindTrial
Sign In

Appraisal of the role of the 68Ga-DOTANOC in the diagnostic by Positron emission tomography (PET) in the study of human tumors of neuroendocrine derivation - ND

Appraisal of the role of the 68Ga-DOTANOC in the diagnostic by Positron emission tomography (PET) in the study of human tumors of neuroendocrine derivation - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-001614-33-IT
Enrollment
Unknown
Registered
2007-09-07
Start date
2006-05-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumors of neuroendocrine derivation MedDRA version: 6.1 Level: HLGT Classification code 10029112

Interventions

Product Name: Ga-DOTANOC PET Pharmaceutical Form: Solution for infusion Current Sponsor code: Ga-DOTANOC PET Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 18

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult subjects (age >18 years) of both sex bearers of tumors of neuroendocrine derivation, joints for specialized appraisal to the Policlinico S.Orsola-Malpighi. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: subjects not in a position to meaning and of wanting, the healthy volunteers, the minors, the women in state of pregnancy, the women during breast-feeding, and patients in emergency situations.

Design outcomes

Primary

MeasureTime frame
Main Objective: earlier diagnosis of the tumors of neuroendocrine derivation;Secondary Objective: therapeutic program personalized for every patient and therefore to reduce the charitable costs;Primary end point(s): to verify the additional role of the PET with 68Ga-DOTANOC in the diagnosis, stage and appraisal of the answer to the therapy and in the programming of an eventual aimed local x-ray, in patients affections from neoplasie of neuroendocrine derivation regarding the other techniques of diagnostic currently routinariamente used—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026